Literature DB >> 10807389

Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

T V Inglesby1, D T Dennis, D A Henderson, J G Bartlett, M S Ascher, E Eitzen, A D Fine, A M Friedlander, J Hauer, J F Koerner, M Layton, J McDade, M T Osterholm, T O'Toole, G Parker, T M Perl, P K Russell, M Schoch-Spana, K Tonat.   

Abstract

OBJECTIVE: The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals following the use of plague as a biological weapon against a civilian population. PARTICIPANTS: The working group included 25 representatives from major academic medical centers and research, government, military, public health, and emergency management institutions and agencies. EVIDENCE: MEDLINE databases were searched from January 1966 to June 1998 for the Medical Subject Headings plague, Yersinia pestis, biological weapon, biological terrorism, biological warfare, and biowarfare. Review of the bibliographies of the references identified by this search led to subsequent identification of relevant references published prior to 1966. In addition, participants identified other unpublished references and sources. Additional MEDLINE searches were conducted through January 2000. CONSENSUS PROCESS: The first draft of the consensus statement was a synthesis of information obtained in the formal evidence-gathering process. The working group was convened to review drafts of the document in October 1998 and May 1999. The final statement incorporates all relevant evidence obtained by the literature search in conjunction with final consensus recommendations supported by all working group members.
CONCLUSIONS: An aerosolized plague weapon could cause fever, cough, chest pain, and hemoptysis with signs consistent with severe pneumonia 1 to 6 days after exposure. Rapid evolution of disease would occur in the 2 to 4 days after symptom onset and would lead to septic shock with high mortality without early treatment. Early treatment and prophylaxis with streptomycin or gentamicin or the tetracycline or fluoroquinolone classes of antimicrobials would be advised.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807389     DOI: 10.1001/jama.283.17.2281

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  296 in total

1.  Emerging illness and bioterrorism: implications for public health.

Authors:  T O'Toole
Journal:  J Urban Health       Date:  2001-06       Impact factor: 3.671

2.  Biological Warfare: Implications for Antimicrobial Use.

Authors:  Ethan Rubinstein; Itzhak Levi
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

Review 3.  Biological warfare and bioterrorism.

Authors:  Nicholas J Beeching; David A B Dance; Alastair R O Miller; Robert C Spencer
Journal:  BMJ       Date:  2002-02-09

Review 4.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

5.  Pulmonary Manifestations of Bioterrorism.

Authors:  Renuka Heddurshetti; Wadchara Pumpradit; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

6.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 7.  [Bioterrorism and primary care].

Authors:  M A Mayer Pujadas; M J Alvarez Pasquín; J Gómez Marco; J Redondo Sánchez; J Muñoz Gutiérrez; M Cereceda Ferrés; C Batalla Martínez; E Comín Bertrán; A Pareja Bezares; R Piñeiro Guerrero; V Niño Martín; J Arranz Izquierdo; P Carceller; E Nodar Martín; J Ortega Martínez; J Vázquez Villegas
Journal:  Aten Primaria       Date:  2002-10-15       Impact factor: 1.137

8.  The genome sequence of Yersinia pestis bacteriophage phiA1122 reveals an intimate history with the coliphage T3 and T7 genomes.

Authors:  Emilio Garcia; Jeffrey M Elliott; Erlan Ramanculov; Patrick S G Chain; May C Chu; Ian J Molineux
Journal:  J Bacteriol       Date:  2003-09       Impact factor: 3.490

9.  Structural Insights into the Yersinia pestis Outer Membrane Protein Ail in Lipid Bilayers.

Authors:  Samit Kumar Dutta; Yong Yao; Francesca M Marassi
Journal:  J Phys Chem B       Date:  2017-08-04       Impact factor: 2.991

Review 10.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.